Ergomed (ERGO)

 

Latest News

Ergomed completes study recruitment ahead of schedule

Ergomed has completed recruitment for its phase IIb proof-of-concept study for PeproStat, its innovative new coagulant, o...

Recruitment complete early for Phase IIb study

RNS Number: 8231L Ergomed plc 24 July 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Ergomed completes Phase IIb study recruitment six months ahead of schedule for its innovative coagulant PeproStat - Top line results expected in Q4 2017, six months earlier than anticipated - Faster than expected recruitment reflects Ergomed's strong CRO capabilities L...

Investor Meeting

RNS Number: 0817K Ergomed plc 04 July 2017 PRESS RELEASE FOR IMMEDIATE RELEASE Investor meeting London, UK - 4 July 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the pharmaceutical industry and the development of new drugs, is today hosting an investor meeting at it...

PeproStat study passes recruitment mid-point

RNS Number: 6561I Ergomed plc 21 June 2017 PRESS RELEASE FOR IMMEDIATE RELEASE PeproStat Phase IIb study passes recruitment mid-point ahead of schedule - Top line results brought forward to Q4 2017 London, UK - 21 June 2017: Ergomed plc (LSE: ERGO) ('Ergomed' or the 'Company'), a company dedicated to the provision of specialised services to the...

All News

DateHeadlineSource
24-07-17Ergomed completes study recruitment ahead of schedule StockMarketWire
24-07-17Recruitment complete early for Phase IIb studyRNS
04-07-17Investor MeetingRNS
21-06-17PeproStat study passes recruitment mid-pointRNS
19-06-17Ergomed resolutions passed at AGMStockMarketWire
16-06-17Result of AGMRNS
16-06-17Ergomed appoints CEOStockMarketWire
16-06-17Appointment of CEORNS
13-06-17Ergomed to present at the Shares Spotlight Evening in Manchester on 29 June 2017StockMarketWire
22-05-17Appointment of N+1 Singer as joint brokerRNS
12-05-17Annual Report and Notice of AGMRNS
08-05-17Ergomed updates in PharmInvent earn-outStockMarketWire
08-05-17Issue of Shares to Former PharmInvent ShareholdersRNS
02-05-17Broker Forecast - Stifel issues a broker note on Ergomed PlcStockMarketWire
02-05-17Broker Forecast - Numis issues a broker note on Ergomed PlcStockMarketWire
02-05-17Co-Development Partner NewsRNS
26-04-1711 shares where positive earnings shocks could trigger ralliesInteractive Investor
13-04-17Board and Management ChangesRNS
04-04-17Director Deals - Ergomed Plc (ERGO)StockMarketWire
04-04-17Director/PDMR ShareholdingRNS
03-04-17Ergomed partner announces successful dataStockMarketWire
03-04-17Partner Asarina Pharma announces successful dataRNS
28-03-17Ergomed revenues up 30%StockMarketWire
28-03-17Ergomed revenues up StockMarketWire
28-03-17Unaudited Preliminary Results for 2016RNS
21-03-17Notice of Preliminary ResultsRNS
20-03-17Ergomed initiates study of PeprostatStockMarketWire
20-03-17Initiates Phase II Study of Topical PeproStatRNS
20-02-17Ergomed notes partner's successful financing roundStockMarketWire
20-02-17Modus Therapeutics Raises SEK 32 MillionRNS
06-02-17Broker Forecast - Numis issues a broker note on Ergomed PlcStockMarketWire
06-02-17Broker Forecast - Stifel issues a broker note on Ergomed PlcStockMarketWire
06-02-17Positive Phase II top-line results of LorediplonRNS
03-02-17Broker Forecast - N+1 Singer issues a broker note on Ergomed PlcStockMarketWire
31-01-17Completion of ZoptrexT Phase 3 Clinical TrialRNS
17-01-1725 momentum stocks for 2017Interactive Investor
17-01-17Ergomed revenues up 26%StockMarketWire
17-01-17Trading StatementRNS
01-12-16Ergomed CFO and general counsel granted optionsStockMarketWire
30-11-16Award of Options by CEO to CFO and General CounselRNS

RSS feeds

  • Editorial news feed for LSE:ERGO Editorial
  • Regulatory news feed for LSE:ERGO Regulatory